Showing 1 - 10 of 546
In the debate on intellectual property rights induced by the Covid-19 pandemic vaccines and treatments are typically referred to as simple products whose manufacturing specifications need only to be shared in order to increase production capacity and accelerate access to all, more specifically...
Persistent link: https://www.econbiz.de/10014346862
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 % of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...
Persistent link: https://www.econbiz.de/10010275649
Markets require informed participants to function efficiently. This paper examines the impact of providing targeted information directly to patients on their purchasing-decisions regarding pharmaceutical drugs. We analyze the effect of informational letters sent by a Swiss health insurer to...
Persistent link: https://www.econbiz.de/10014564096
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
Many politicians blame physician dispensing (PD) to increase health care expenditure and to undermine independence of drug prescription and income leading to a suboptimal medication. Therefore, PD is not allowed in most OECD countries. In Switzerland, PD is allowed in some regions depending on...
Persistent link: https://www.econbiz.de/10003900934
We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when...
Persistent link: https://www.econbiz.de/10003471161
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10003373751
Using an extensive longitudinal dataset extracted from the Norwegian Prescription Database (NorPD) containing all prescriptions written in the period January 2004 to June 2007, we selected two particular drugs (chemical substances) used against cholesterol. The two brand-name products on the...
Persistent link: https://www.econbiz.de/10008697144
Dieser Beitrag entwickelt einen Vorschlag zur indikationsspezifischen Kosten-Nutzen-Bewertung. Zentrales Konzept ist ein sozialer Gesundheitsindex, der die Leistung des Gesundheitswesens misst. Er berücksichtigt nicht nur das Niveau der Gesundheit in der Bevölkerung, sondern auch deren...
Persistent link: https://www.econbiz.de/10003950825
This paper explores different empirical strategies to examine the effect of cost sharing for prescription drugs in some dimensions of medication-related quality, namely the probability of inappropriate prescription drug use among United States seniors. Using data from 1996 to 2005, we explore...
Persistent link: https://www.econbiz.de/10003951612